Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3226 - The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy;  Targeted Therapy

Tumour Site

Melanoma

Presenters

Anna Czarnecka

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

A.M. Czarnecka, P. Teterycz, I. Lugowska, P. Rogala, T. Switaj, P.L. Rutkowski

Author affiliations

  • Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, 02-781 - Warsaw/PL
More

Resources

Abstract 3226

Background

BRAF V600 mutation was considered as a negative prognostic factor in metastatic (stage IV) melanoma patients (pts). Nowadays, two effective systemic treatment modalities - targeted therapy with BRAF+MEK inhibitors and immunotherapy are available for this group of pts contrary to BRAF-wild-type patients where only immunotherapy is used. It is unclear what is the outcome of therapy and treatment sequence in advanced melanoma patients with BRAF-positive and negative patients in the routine practice.

Methods

In this retrospective one-center study, we included 276 (134, 48.6% BRAF V600 mutated) consecutive pts with unresectable/metastatic stage III/IV melanoma treated between 01/2016 and 02/2018. Kaplan-Meier survival probability estimation and Cox’s proportional hazards model were used for analysis.

Results

The first line treatment comprised of anti-PD1 antibodies (in 167 cases, i.e. all BRAF-negative and 25 BRAF-mutant pts) and BRAF/MEK inhibitors (in 109 cases BRAF+ pts). The 1-year overall survival (OS) rates were 61.6% (95% confidence interval, CI: 53.4-71.1) in BRAF-negative pts, 61.1% (95%CI: 51.8-72.1) and 77.3% (95%CI: 61.6-97.1) in BRAF-mutated pts who started BRAF/MEK inhibitors or anty-PD1 antibodies as the first line treatment, respectively. In the multivariable model adjusted for age, sex and LDH level BRAF-mutated pts who received anti-PD1 as 1st line treatment had slightly worse first line progression-free survival (HR: 1.91, 95%CI: 1.00-3.63, p = 0.05), but there were no differences in the multivariable model for OS (HR: 0.67, 95%CI: 0.28-1.58, p = 0.35).

Conclusions

The short-term outcomes of advanced melanoma patients treated with modern systemic therapies are similar independently of BRAF V600 mutation status. Numerically, the best survival rates were reached in BRAF-positive pts who received anti-PD1 antibodies as the 1st line treatment, but this effect needs to be confirmed in a larger population study.

Clinical trial identification

Legal entity responsible for the study

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland.

Funding

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland.

Editorial Acknowledgement

Disclosure

A.M. Czarnecka: Honoraria, Speakers’ bureau, Travel expenses reimbursement: Bristol-Myers Squibb, Roche, Novartis, Merck, Pfizer, GlaxoSmithKline. P. Teterycz: Honoraria, Travel expenses reimbursement: Roche, Eli Lilly, Bayer, Novartis. I. Lugowska, P. Rogala, T. Switaj: Honoraria, Speakers' bureau, Travel expenses reimbursement: Bristol-Myers Squibb, Roche, Novartis, Merck, Pfizer, GlaxoSmithKline. P.L. Rutkowski: Honoraria: Bristol-Myers Squibb, Roche, Novartis, Merck, Sharp & Dohme, GlaxoSmithKline; Paid consulting role with Bristol-Myers Squibb, Roche, Merck, Sharp & Dohme, Blueprint Medicines, Amgen; Speakers’ bureau: Novartis, Pfizer, Merck, Sharp & Dohme; Institutional research funding: Bristol-Myers Squibb, Novartis; Travel expenses reimbursement: Novartis,Orphan Drugs.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.